The Academic Breast Cancer Consortium (ABRCC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at the most prestigious institutions in the USA and Canada. It provides a platform on which to design and develop state of the art targeted and combination studies for cancer drug treatments.
Watch the PharmaVoice One on One video interview below to learn more about the latest in breast cancer research from Dr. Peter Kabos, Director of the Academic Breast Cancer Consortium and Assistant Professor in the Division of Medical Oncology at University of Colorado Cancer Center.
About Peter Kabos, MD
Dr. Peter Kabos is Assistant Professor, Division of Medical Oncology at University of Colorado Cancer Center. Dr. Kabos joined the UCD faculty in July 2009 and was a member of the breast oncology program there. He spent four years as a post-doctoral research fellow at Cedars-Sinai Medical Center studying the biology of normal and cancer stem cells in gliomas. He completed his Internal Medicine residency training at USC Keck School of Medicine in Los Angeles and a fellowship in Hematology/Oncology at the University of Colorado Denver. He received his MD from Comenius University, Slovakia.
His research focus is in translating preclinical findings into novel treatments for patients with breast cancer. The Kabos Lab at the university focuses on the role of breast cancer stem cells and tumor microenvironment in treatment resistance.
His specialties and certifications include: Internal Medicine, Board Certification (2006); Internal Medicine – Medical Oncology, Board Certification (2009). His awards and honors include the ASCO Young Investigator Award and a Spore Seed Grant for Breast Cancer.